Morana Jovan-Embiricos
CIK 1575745 · last filed 2026-06-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ALVR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
201 BROADWAY, 6TH FLOOR
BOSTON, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KLRS | Director | — | $2.39 | — | $0 | 2 | 2026-06-04 |
| Kalaris Therapeutics, Inc. (ALVR) Delisted | Director | 42,081 | $9.81 | $412.8K | $48.59M | 11 | 2024-06-07 |
| CGEM | Director | 578,214 | $12.05 | $6.97M | -$5.35M | 4 | 2022-06-28 |
| TCR2 THERAPEUTICS INC. (TCRR) Delisted | 10%+ Owner | 392,185 | $1.48 | $580.4K | -$58.9K | 1 | 2019-10-24 |
| Radius Health, Inc. (RDUS) Delisted | Director | 0 | $30.00 | $0 | $0 | 5 | 2015-01-20 |
Recent Filings · Page 2 of 3
23 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-11-15 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −800 | -$19.8K | EDGAR |
| 2021-11-09 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −12,196 | -$302.5K | EDGAR |
| 2021-10-29 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −2,200 | -$54.5K | EDGAR |
| 2021-10-25 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −13,592 | -$337.0K | EDGAR |
| 2021-05-27 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-08-06 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Mixed | +18,379,398 | $49.30M | EDGAR |
| 2020-07-31 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-10-24 | TCR2 THERAPEUTICS INC. (TCRR) Delisted | Sell (S) | −3,888 | -$58.9K | EDGAR |
| 2015-01-20 | Radius Health, Inc. (RDUS) Delisted | Other (J) | — | $0 | EDGAR |
| 2015-01-15 | Radius Health, Inc. (RDUS) Delisted | Other (J) | −587,500 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.